Search the Newsreel

Quantinno Capital Management LP Decreases Stock Holdings in NewMarket Corporation $NEU

Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties

Entropy Neurodynamics Issues Director Fee Shares, Confirms Regulatory Compliance

Neuland Laboratories Stock Surges 7% After Q1 Profit Swells 10-Fold

Neuland Laboratories shares surge over 11%, hit record high on strong June quarter earnings

Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this …

Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading

Jupiter Neurosciences (JUNS) has granted 472,222 stock options to director Andrew Jon Cutler under its 2025 Equity Incentive Plan. This grant, with an exercise price of $0.0900 per share, is in lieu of cash compensation for his board service. The options vest with 25% …

Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced a 1-for-75 reverse stock split, approved by its board of directors and stockholders. This action is intended to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding …

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue …

Kirloskar Pneumatic fixes Aug 18 as record date for stock split

Alto Neuroscience (ANRO) Projected to Announce Earnings on Wednesday

Why NewMarket (NEU) Is Up 13.6% After Robust Q2 Earnings And Aggressive Share Buybacks

Neuland Laboratories Q2 Results: Earnings call audio uploaded for investors

ClearPoint Neuro (CLPT) Stock Sinks As Cash Burn Deepens

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating CBIZ, Inc. (CBZ), Safety Insurance Group Inc. (SAFT), Neuphoria Therapeutics Inc. (NEUP), and TriCo Bancshares (TCBK) for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed transactions. The …

ClearPoint Neuro (CLPT) investors disclose 7.45% beneficial ownership stake

An amended Schedule 13G filing reveals that investors led by Bigger Capital Fund, LP have disclosed a beneficial ownership stake of 7.45% in ClearPoint Neuro (CLPT). Michael Bigger, through various affiliations and personal holdings, is deemed to beneficially own 2,272,980 shares of the common …

ProMIS schedules 4:30 p.m. webcast for Aug. 13 update

ProMIS Neurosciences (Nasdaq: PMN) will report its second-quarter 2026 financial results and provide a business update on August 13, 2026. The company will host an investor conference call and webcast on the same day at 4:30 p.m. Eastern Time. U.S. investors can dial 1-877-407-9208, …

NeuroPace (NPCE) Expected to Release Earnings on Tuesday

NeuroPace (NPCE) is scheduled to release its Q2 2026 earnings after market close on Tuesday, August 11th. Analysts anticipate a loss of $0.19 per share on revenue of $22.6 million. In the previous quarter, the company surpassed estimates with a loss of $0.13 per …

Stifel cuts Clearpoint Neuro stock price target on guidance cut

Stifel lowered its price target for Clearpoint Neuro (NASDAQ:CLPT) from $25 to $22, while maintaining a Buy rating, following the company's guidance cut. Clearpoint Neuro reported second-quarter revenue of $10.9 million, missing estimates, and reduced its 2026 revenue guidance by 7% to $50 million. …

Jorey Chernett gains board input rights at Neuronetics (STIM)

Jorey Chernett, a major shareholder in Neuronetics, Inc. (STIM), has increased his beneficial ownership to 15.22% with 10,588,988 shares. He has acquired these shares using personal funds totaling approximately $20.68 million. Chernett and Neuronetics have reached an agreement granting him the opportunity to recommend …

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

ClearPoint Neuro (CLPT) reported Q2 2026 revenue of $10.88 million, an 18% increase year-over-year, but missed the Zacks Consensus Estimate of $13 million. The company posted an EPS of -$0.38, also missing the consensus estimate of -$0.29. Key metric analysis revealed varied performance across …

Clearpoint Neuro Inc reports results for the quarter ended June 30 - Earnings Summary

Clearpoint Neuro Inc. has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv, gives an overview of the company's financial performance during this period.

Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise

Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold these 2,500 shares at a weighted average price of $16.0116. These transactions, executed under a Rule 10b5-1 trading plan adopted in September 2025, resulted in …

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has received a "Moderate Buy" consensus recommendation from ten analysts, with an average 12-month price target of $19.29, significantly above its recent opening price of $13.50. The company recently surpassed earnings expectations, reporting a smaller adjusted loss and higher revenue than …

ClearPoint Neuro outlines $48M-$52M 2026 revenue guidance as it prioritizes CAL, clinical capacity, and focused ultrasound partnership

Earnings Call Insights: ClearPoint Neuro (CLPT) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 in itself has been an exciting one and possibly one of the most important series of events in our history," said Joseph Burnett (President, CEO & Director), adding …

ClearPoint Neuro (Nasdaq: CLPT) grows Q2 revenue and updates 2026 outlook

ClearPoint Neuro (CLPT) reported strong Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by significant growth in neurosurgery navigation and therapy. The company has updated its 2026 revenue guidance to between $48.0 million and $52.0 million, reflecting strategic investments in clinical …

Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV

Entropy Neurodynamics Gains Ethics Approval for Eight-Indication TRP-8803 Trial

Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm

Kaskela Law LLC has initiated an investigation into Jupiter Neurosciences, Inc. (NASDAQ:JUNS) on behalf of its shareholders. The firm is looking into whether Jupiter and its officers/directors violated securities laws or breached fiduciary duties. Long-term JUNS investors are encouraged to contact Kaskela Law LLC …

Neuronetics shareholder Chernett seeks board seat in push to maximize shareholder value

Neuronetics has reached an agreement with its second-largest shareholder, Jorey Chernett, regarding board representation. Chernett, an activist shareholder, will recommend a new director and has expressed support for the company's management following discussions on its financial health and capital optimization. This development comes as …

Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com

Contineum Therapeutics CEO Carmine N. Stengone sold 2,500 shares of the company's Class A Common Stock for $40,029 on August 3, 2026, through a pre-arranged 10b5-1 trading plan. On the same day, he also acquired 2,500 shares by exercising stock options for $2,525. The …

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO)

Levi & Korsinsky LLP has filed a class action lawsuit against Alto Neuroscience, Inc. (ANRO) on behalf of investors who suffered losses. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiveness of its product pipeline, ALTO-100, for treating major …

Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com

This article reports on a Form 4 filing for Contineum Therapeutics Inc. on August 3rd, as reported by Investing.com. It is a brief financial announcement indicating a regulatory disclosure for the company. The article includes standard market data and links to related financial news …

Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Eleven analysts have given Alto Neuroscience, Inc. (NYSE:ANRO) a consensus "Moderate Buy" rating, with eight recommending a buy, two a sell, and one a hold. The average 12-month price target is $35.25, significantly higher than its opening price of $27.09. Despite increased institutional investment …

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.29 loss, and revenues of $10.88 million, falling short of estimates by 16.31%. The company's shares have gained 9.2% year-to-date, slightly underperforming the S&P 500. …